Cutis
Medical College of Virginia Hospitals, Virginia Commonwealth University Health System, Richmond, USA.
Published: July 2007
We report a case of a 41-year-old black man who presented with chronic severe atopic dermatitis that only responded to oral corticosteroids. Failed treatments for this patient included topical corticosteroids, topical pimecrolimus, oral prednisone, oral antihistamines, azathioprine, and narrowband UV light therapy. Only oral corticosteroids provided significant relief. The patient had an immunoglobulin E (IgE) level of 7340 IU/mL (reference range, 0-100 IU/mL). He responded to a 12-week course of omalizumab, a humanized monoclonal anti-LgE antibody currently indicated for patients 12 years and older with moderate to severe persistent asthma. Our patient experienced no adverse events throughout the course of treatment. We suggest that omalizumab may have a role in the treatment of isolated atopic dermatitis in the adult population.
Download full-text PDF |
Source |
---|
Tissue Eng Regen Med
January 2025
Department of Systems Biotechnology, Chung-Ang University, Anseong-Si, Gyeonggi-Do, 17546, Republic of Korea.
Background: Exosomes and exosome mimetics are used as alternatives to cell therapy. They have shown potential in treating skin disorders by fortifying the skin barrier, mediating angiogenesis, and regulating the immune response while minimizing side effects. Currently, numerous studies have applied exosome therapy to treat atopic dermatitis (AD) caused by a weakened skin barrier and chronic inflammation.
View Article and Find Full Text PDFJ Dermatol
January 2025
Department of Dermatology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
Vitiligo is a chronic autoimmune disorder that profoundly impacts patients' quality of life. Real-world data on vitiligo in Japan are limited. This descriptive, cross-sectional study used a claims database to evaluate vitiligo prevalence, patient demographics, treatments, and comorbidities in Japanese patients with vitiligo.
View Article and Find Full Text PDFJ Allergy Clin Immunol Glob
February 2025
Division of Allergy and Immunology, Department of Medicine and Department of Pediatrics, Rush University Medical Center, Chicago, Ill.
Background: The incidence of food allergy (FA) has been increasing worldwide, causing growing concern on a global scale.
Objective: This birth cohort study analyzes the incidence of reported FA and other atopic comorbidities in children from birth to age 2 years who were living in 4 urban and semiurban areas in Iran.
Methods: Children were followed from birth until age 24 months, with follow-up questionnaires administered through parent or guardian interviews conducted when the children were aged 2, 4, 6, 12, and 24 months.
J Clin Aesthet Dermatol
January 2025
Dr. Warren and Ms. Sanchez are with Derm Texas in Dallas, Texas.
Vitiligo is an autoimmune disorder that causes melanocyte damage and pigment loss. The clinical presentation of vitiligo consists of patchy areas of lighter skin and results from a loss of functioning melanocytes and may be more visible in darker skin toned patients. Vitiligo affects approximately 2 percent of children and adolescents in the United States, with half of the affected cases undiagnosed.
View Article and Find Full Text PDFJ Clin Aesthet Dermatol
January 2025
Ms. Pomaville is with Forefront Dermatology in Berwyn, Illinois; the Marquette University College of Health Sciences, PA Studies Program in Milwaukee, Wisconsin; and the University of Dubuque, MSPAS Program, in Dubuque, Iowa.
Seborrheic dermatitis (SD) is an inflammatory skin disease with multifactorial etiology, involving genetic and environmental factors. Many conventional therapies for SD (ie, topical antifungals, topical corticosteroids) are associated with incomplete efficacy, frequent and sometimes rapid disease recurrence, and restrictions on duration of therapy and anatomic sites of application. This may be because they cannot target multiple disease processes and/or are limited by safety considerations.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.